CDC42 and prostate cancer: Our data showing that depletion of tumour cell CD99 increases CDC42 activity and enhances the spreading and intercalation of tumour cells into the endothelium is consistent with the work of Reymond et al. (2012), which showed that CDC42 depletion reduced both tumour cell spreading on endothelial monolayers and the metastasis of breast (MDA-MB-231) and prostate cancer (PC3) cells in vivo.